NEW YORK (GenomeWeb) – UK-based protein characterization firm Fluidic Analytics said today it has raised $31 million in a Series C funding round that it plans to use to develop and commercialize instruments for protein analysis.
The financing was led by European venture capital fund Draper Esprit, which was joined by other investors, including Delin Ventures, BGF, IQ Capital, and Amadeus Capital Partners.
"The financing will power the global commercial launch of our Fluidity One system and enable our team to bring our next two lab-tools products to market," Andrew Lynn, Fluidic Analytics' CEO, said in a statement. "It will also allow us to advance a number of high-potential clinical applications that could help us make an even bigger impact on the world."
Launched in September, the Fluidity One instrument monitors the diffusion of proteins as they flow through a microfluidic channel to assess their size and concentration, allowing researchers to identify, for instance, protein aggregation linked to disease processes or protein interactions
The company is also working on instruments for the analysis of labeled proteins mixed into complex matrices, like blood or cell lysates, and for proteome-scale analysis of protein interactions in biological samples.